Arcutis Biotherapeutics annual depreciation and amortization
2018
2019
2020
2021
2022
2023
2024
2025
Arcutis Biotherapeutics Depreciation & Amortization Growth & History (ARQT)
Arcutis Biotherapeutics's depreciation and amortization was $5.4M for fiscal 2025.
View full Arcutis Biotherapeutics company overviewArcutis Biotherapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5.4M | $2.8M | +109.73% |
| 2024 | 2024-12-31 | $2.6M | $1.0M | +65.10% |
| 2023 | 2023-12-31 | $1.6M | $616,000 | +65.95% |
| 2022 | 2022-12-31 | $934,000 | $480,000 | +105.73% |
| 2021 | 2021-12-31 | $454,000 | $332,000 | +272.13% |
| 2020 | 2020-12-31 | $122,000 | $54,000 | +79.41% |
| 2019 | 2019-12-31 | $68,000 | $68,000 | — |
| 2018 | 2018-12-31 | $0 | — | — |
Arcutis Biotherapeutics quarterly depreciation and amortization
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $563,000 | $0 | 0.00% |
| Q1 2026 | 2026-03-31 | $562,000 | −$2.6M | −82.06% |
| Q4 2025 | 2025-12-31 | $563,000 | — | — |
| Q3 2025 | 2025-09-30 | $562,000 | −$870,000 | −60.75% |
| Q2 2025 | 2025-06-30 | $563,000 | $199,000 | +54.67% |
| Q1 2025 | 2025-03-31 | $3.1M | $2.8M | +774.86% |
| Q3 2024 | 2024-09-30 | $1.4M | −$186.8M | −99.24% |
| Q2 2024 | 2024-06-30 | $364,000 | −$34,000 | −8.54% |
| Q1 2024 | 2024-03-31 | $358,000 | −$5,000 | −1.38% |
| Q3 2023 | 2023-09-30 | $188.2M | $187.9M | +66637.59% |
| Q2 2023 | 2023-06-30 | $398,000 | $243,000 | +156.77% |
| Q1 2023 | 2023-03-31 | $363,000 | $213,000 | +142.00% |
| Q3 2022 | 2022-09-30 | $282,000 | $166,000 | +143.10% |
| Q2 2022 | 2022-06-30 | $155,000 | $51,000 | +49.04% |
| Q1 2022 | 2022-03-31 | $150,000 | $52,000 | +53.06% |
| Q3 2021 | 2021-09-30 | $116,000 | $86,000 | +286.67% |
| Q2 2021 | 2021-06-30 | $104,000 | $74,000 | +246.67% |
| Q1 2021 | 2021-03-31 | $98,000 | $71,000 | +262.96% |
| Q3 2020 | 2020-09-30 | $30,000 | $11,000 | +57.89% |
| Q2 2020 | 2020-06-30 | $30,000 | $10,000 | +50.00% |
| Q1 2020 | 2020-03-31 | $27,000 | $22,000 | +440.00% |
| Q3 2019 | 2019-09-30 | $19,000 | — | — |
| Q2 2019 | 2019-06-30 | $20,000 | — | — |
| Q1 2019 | 2019-03-31 | $5,000 | — | — |
Arcutis Biotherapeutics depreciation and amortization trends
Over the last five fiscal years, Arcutis Biotherapeutics's depreciation and amortization increased from $122,000 to $5.4M, a change of $5.2M. The latest reported quarter, Q2 2026, shows $563,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Arcutis Biotherapeutics source filings ↗